Aligos Therapeutics Files 2025 Proxy Statement
Ticker: ALGS · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: ALGS
TL;DR
Aligos Therapeutics (ALGS) filed its proxy statement for the 2025 shareholder meeting. Vote your shares!
AI Summary
Aligos Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 28, 2025, for its annual meeting of stockholders. The filing covers the fiscal year ending December 31, 2024, and outlines matters to be voted on by shareholders, including the election of directors and other corporate governance items. The company is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing provides shareholders with crucial information regarding corporate governance and voting matters, enabling them to make informed decisions about the company's leadership and direction.
Risk Assessment
Risk Level: low — This is a routine proxy filing, not indicating any immediate financial or operational risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (The proxy statement covers the company's performance and governance up to this date.)
- 20250428 — Filing Date (This is the date Aligos Therapeutics filed its definitive proxy statement with the SEC.)
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Registrant
- 0001799448 (company) — Central Index Key
- 2836 (company) — Standard Industrial Classification Code
- DE (company) — State of Incorporation
- 1231 (company) — Fiscal Year End
- 001-39617 (company) — SEC File Number
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming annual or special meeting, providing details on matters to be voted upon.
When is Aligos Therapeutics' fiscal year end?
Aligos Therapeutics' fiscal year ends on December 31st, as indicated in the filing.
What is the SEC file number for Aligos Therapeutics?
The SEC file number for Aligos Therapeutics is 001-39617.
What is the business address of Aligos Therapeutics?
The business address for Aligos Therapeutics is One Corporate Dr., 2nd Floor, South San Francisco, CA 94080.
What is the SIC code for Aligos Therapeutics?
Aligos Therapeutics' Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Aligos Therapeutics, Inc. (ALGS).